Clinical evaluation of EB-382 (alminoprofen) on postexodontic pain

A double blind comparative trial with indomethacin

Abstract

A multi-clinic double blind study was conducted to evaluate the analgesic efficacy and safety of EB-382, in comparison with indomethacin on the postexodontic pain.
1) Total prescription cases were 500. Analized cases were 270. Drop-out and excluded cases were 5 and 7 each. Clinically evaluated cases were 258.
2) EB-382 group was superior to indomethacin group on the ratio of“markedly improved, ”“over moderately improved, ”and“over slightly improved, ”in global improvement rating of a pain.
3) With respect to time till appearance to effect after admistration, EB-382 group was significantly faster than indomethacin group (p<0.01) .
4) Side effects were reported 4 cases in 124 cases of EB-382 group and 6 cases in 139 cases of indomethacin group. The side-effects were almost mild.
5) EB-382 group was superior to indomethacin group on the ratio of“mardedly useful”“over moderately useful” and “over slightly usefu 1” in overall clinical evaluation rating.
Summarizing the above results, it can be concluded that EB-382 is a useful drug for exodontic pain.